Description
Buy ACE-083 online
Also referred to as ACVR2B or ActRIIB-IgG1, is a synthetically produced protein that was originally developed by two bio-pharmaceutical companies, namely Acceleron and Shire, for its potential ability to inhibit myostatin and other naturally occurring proteins that limit muscle growth. Buy ACE-083 online
It was hypothesized that ACE-031 would act as a decoy receptor for the catabolic proteins, specifically myostatin, and bind to them in an effort to keep them away from muscle fibers.
Numerous studies have been conducted to determine if ACE-031 is an effective treatment for children who have Duchenne Muscular Dystrophy (DMD).
What is Myostatin (Buy ACE-083 online UK)?
Myostatin, abbreviated GDF-8 (Growth Differentiation Factor-8), is a protein naturally produced in mammals, which acts on muscle cells as an inhibitor of myogenesis (differentiation and growth of muscle cells).
The gene encoding myostatin was discovered in 1997 by geneticists Se-Jin Lee and Alexandra McPherron who produced a strain of mutant mice that lack the gene. These scientists produced a strain of mice that lacked the gene and had approximately twice as much muscle as normal mice.
ACE-083 is designed to bind to and inhibit select proteins in the TGF-beta protein superfamily that negatively regulate (reduce) muscle growth, such as activins and myostatin (GDF8). This “Myostatin +” approach, is believed to increase muscle mass and strength in the muscle where the drug is administered. Untreated muscles or other organs are not affected, reducing the potential for systemic side effects.
Based on encouraging Part 1 results from our two-part Phase 2 trials in FSHD and CMT, we have initiated Part 2 of both of the trials.
ACE-083 is an investigational therapy that is not approved for any use in any country.
ACE-083 is the lead product candidate in our neuromuscular therapeutic program. It is a locally active agent that may be useful for diseases of focal muscle loss such as muscular dystrophies, such as facioscapulohumeral muscular dystrophy (FSHD) and Charcot-Marie-Tooth disease (CMT). The U.S. FDA has granted ACE-083 Fast Track and Orphan Drug designations in FSHD and CMT. ACE-083 is designed to increase strength and function in specific target muscles for improved patient function and quality of life.
